AndhraNews.net
Home » Features » Health » Muscular dystrophy

Muscular dystrophy


About Muscular dystrophy

Muscular dystrophy (MD) is a group of muscle diseases that weaken the musculoskeletal system and hamper locomotion. Muscular dystrophies are characterized by progressive skeletal muscle weakness, defects in muscle proteins, and the death of muscle cells and tissue.

Duchenne muscular dystrophy

Duchenne muscular dystrophy is an inherited disease. It is characterized by progressive muscle weakness because of a mutated protein gene. Duchenne muscular dystrophy usually affects boys between 2 and 6 years old. The child will be confined to wheelchair for the first few years, before the disease progresses weakening his heart and killing him by the time he reaches early 20's.

Surgery

A groundbreaking surgery was performed on a Duchenne patient in United States for the first time. The patient is 29 years old and was expected to live for just one year. However, after the surgery, it was learnt that he will no longer have an expiration date. The doctors implanted Jason's Left Ventricular Assist Device (LVAD) on 5 September 2012 at Cincinnati Children's Hospital.

Recent developments on Muscular dystrophy

  • A new drug has offered hope to people suffering from the most severe type of muscular dystrophy after achieving spectacular results in animal tests.
  • A Sydney scientists group achieved breakthrough in using adult stem cells to re-grow damaged muscle tissue in mice, and thereby moved a step closer to realising a potential new therapy for incurable diseases like muscular dystrophy.
  • Scientists have found that genes important for forming muscle cells in embryos and newborns are not needed in adult muscle stem cells to regenerate muscles after injury.
  • A novel study by British scientists have traced the origin of two of the most common and potentially fatal muscular dystrophy to its prenatal roots.
  • Scientists have achieved a significant breakthrough in creating in the lab a set of new stem cell lines that can make it possible to explore 10 different genetic disorders, including muscular dystrophy, juvenile diabetes, and Parkinsons disease.
  • University of Missouri (MU) research on animals found gene therapy with a proven longevity gene to energize during exercise
  • Scientists have come up with a new therapy that has the potential to treat people with Duchenne muscular dystrophy, a fatal disease and the most common form of muscular dystrophy in children.
  • A new study conducted by researchers from the UK and US has revealed that Myostatin, a protein that blocks muscle growth, seems to be an effective potential therapeutic target for safe muscular dystrophy treatment.
  • Claim researchers from Universite Lavals Faculty of Medicine and the CHUQ Research Center claims that it possible to repair the defective gene responsible for Duchenne muscular dystrophy
  • University of Nevada School of Medicine Current research suggests that a protein, which helps cells stick together, may lead to enhanced muscle repair in muscular dystrophy.
  • A study in monkeys has put scientists one step closer to clinical trials to test a gene delivery strategy to improve muscle mass and function in patients with certain degenerative muscle disorders.

Muscular dystrophy in News

Kyoto University's Center for iPS Cell Research Application and Takeda Launch the Joint Program for iPS Cell Applications Research at the Shonan Research Center (T-CiRA)
Business Wire IndiaThe Center for iPS Cell Research and Application (CiRA) at Kyoto University and Takeda Pharmaceutical Company Limited (Takeda) announced today the initiation of the joint research program to develop clinical applications of induced pluripotent stem cells

Curb Energy Consumption
(Family Features) Water heaters are energy intensive appliances. In fact, they are the second largest energy user in the home, and as they age, they become less efficient, requiring even more energy.

Cushman & Wakefield/Commerce Announces the Promotion of Dan Palmeri to Senior Director
Cushman & Wakefield/Commerce is proud to announce the promotion of Dan Palmeri from Director to Senior Director. As a 13-year resident of Las Vegas, Palmeri originally joined Cushman & Wakefield/Commerce in 2012.

Santhera Completed Share Placement and Raised CHF 54.8 Million
Santhera Pharmaceuticals Holding AG /Santhera Completed Share Placement and Raised CHF 54.8 Million . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Santhera Launches Placement of up to 500,000 New Shares Through an Accelerated Bookbuilding Procedure
Santhera Pharmaceuticals Holding AG /Santhera Launches Placement of up to 500,000 New Shares Through an Accelerated Bookbuilding Procedure . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Santhera Reports New Data and Updates on Regulatory Filings for Raxone® (idebenone) in Duchenne Muscular Dystrophy (DMD)
Santhera Pharmaceuticals Holding AG /Santhera Reports New Data and Updates on Regulatory Filings for Raxone® (idebenone) in Duchenne Muscular Dystrophy (DMD) . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Santhera and Parent Project Muscular Dystrophy (PPMD) Announce Results of Benefit / Risk Survey in patients with Duchenne Muscular Dystrophy (DMD)
Santhera Pharmaceuticals Holding AG /Santhera and Parent Project Muscular Dystrophy (PPMD) Announce Results of Benefit / Risk Survey in patients with Duchenne Muscular Dystrophy (DMD) . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Alorica to Participate in Muscular Dystrophy Association Lock-Up Event to Raise Awareness for Neuromuscular Disease
Alorica, a worldwide leading provider of customer management outsourcing solutions, today announced that it has teamed up with the Muscular Dystrophy Association (MDA), a leading non-profit health organization, to help raise money at its annual lock-up charity event on October 15, 2015

Convaid to Ship Donated Wheelchairs to Mission Emanuel in Dominican Republic
TORRANCE, CA--(Marketwired - September 10, 2015) - Convaid, Inc

Santhera Receives Rare Pediatric Disease Designation from FDA for Idebenone for the Treatment of Duchenne Muscular Dystrophy
Santhera Pharmaceuticals Holding AG /Santhera Receives Rare Pediatric Disease Designation from FDA for Idebenone for the Treatment of Duchenne Muscular Dystrophy . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Santhera Raised CHF 27.7 Million of New Capital
Santhera Pharmaceuticals Holding AG /Santhera Raised CHF 27.7 Million of New Capital. Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Santhera to Raise Capital Through Sale of Newly Created Shares
Santhera Pharmaceuticals Holding AG /Santhera to Raise Capital Through Sale of Newly Created Shares . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

FDA approves Novartis drug Odomzo® (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer
Novartis International AG /FDA approves Novartis drug Odomzo® (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Santhera Announces First Patient Dosing with Omigapil in Congenital Muscular Dystrophy (CMD) and Full Patient Recruitment of CALLISTO Study
Santhera Pharmaceuticals Holding AG /Santhera Announces First Patient Dosing with Omigapil in Congenital Muscular Dystrophy (CMD) and Full Patient Recruitment of CALLISTO Study . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

BB BIOTECH AG: Biotech sector weathers the market consolidation
BB BIOTECH AG /BB BIOTECH AG: Biotech sector weathers the market consolidation. Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Kathy Bates to Kick Off 1st Annual CA Run/Walk to Fight Lymphedema & Lymphatic Diseases
The Lymphatic Education & Research Network (LE&RN) announced that Academy Award-winner and LE&RN Spokesperson Kathy Bates will kick off the first annual CA Run/Walk to Fight Lymphedema & Lymphatic Diseases in Santa Monica on June 28, 2015.

Santhera Appoints Chief Financial Officer
Santhera Pharmaceuticals Holding AG /Santhera Appoints Chief Financial Officer. Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

MaestroSoft Reinvents Mobile Fundraising With Text2Fund
MaestroSoft, the premier provider of charity fundraising solutions utilized by major organizations such as the Muscular Dystrophy Association, today announced the launch of Text2Fund, an easy and ultra-convenient way to immediately contribute to any campaign using a PayPal account by simply typing a keyword and sending a text message

Convaid Announces Release of 35 Trekker Product Videos
TORRANCE, CA--(Marketwired - June 15, 2015) - Convaid, Inc., a Torrance-based manufacturer of custom-made, compact lightweight adaptive-assisted wheelchairs today announced the deployment of 35 micro videos depicting various aspects of its latest offering, the Trekker.

Convaid to Present Trekker at 2015 South Bay Kidsfest
TORRANCE, CA--(Marketwired - June 10, 2015) - Convaid, Inc

Santhera Reports Positive Outcome for Catena(R)/Raxone(R) in Phase III DMD Trial Supported by Additional Respiratory Function Data
Santhera Pharmaceuticals (SIX: SANN) today reported that the results of secondary respiratory function endpoints from the on-going analysis of the DELOS trial in Duchenne Muscular Dystrophy (DMD) corroborate the positive outcome for the primary endpoint. These data provide further supportive evidence of a treatment benefit for Catena®/Raxone® in DMD.

Santhera Announces Successful Outcome of Phase III Study with Catena(R)/Raxone(R) in Duchenne Muscular Dystrophy
Santhera Pharmaceuticals (SIX: SANN) announces today that its Phase III DELOS study of orally administered Catena®/Raxone® (INN: idebenone) in patients with Duchenne Muscular Dystrophy (DMD) met the primary endpoint and achieved its primary objective of delaying the loss of respiratory function compared to placebo.

Overtech Appoints New Chief Medical Officer and Managing Director of Beatmungspflege 24 GmbH
Overtech Corp. (OTCQB: OVET) Overtech Corp. (the "Company" or "Overtech") and its wholly owned subsidiary Medicus Homecare Inc. ("Medicus"), are pleased to announce the appointment of Dr. Herald Hertl as Chief Medical Officer and Managing Director of Beatmungspflege 24 GmbH.

Zumba's Charity Platform Moves the World; Raises Millions for Breast Cancer Research & Lou Gehrig's Disease
MIAMI, FL--(Marketwired - December 01, 2014) - Global fitness leader Zumba announces today that, with the culmination of its latest campaign, close to six million dollars has been raised via its corporate social responsibility initiatives for important causes including finding a cure for Lou Gehrig's disease and funding preventative breast cancer research.

Santhera and Parent Project Muscular Dystrophy (PPMD) Team Up on Benefit/Risk Study in Duchenne Muscular Dystrophy
Santhera Pharmaceuticals Holding AG /Santhera and Parent Project Muscular Dystrophy (PPMD) Team Up on Benefit/Risk Study in Duchenne Muscular Dystrophy . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Overtech Completes Acquisition of Beatmungspflege 24 GmbH
Overtech Corp. (OTCBB: OVET) Overtech Corp. (the "Company" or "Overtech") is pleased to announce the Closing of the Share Purchase Agreement (the "Share Purchase Agreement") dated September 3, 2014 with Overtech, its wholly-owned subsidiary, Medicus Homecare Inc., Dr

International Stem Cell Corporation Provides Update on the Status of Its Parkinson's Disease Program
CARLSBAD, CA--(Marketwired - October 02, 2014) - International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell based therapies and biomedical products today provided an update on the status of Parkinson's disease preclinical program. The program continues to progress on the plan developed with input from the FDA

Overtech Provides Update on Acquisition of Beatmungspflege 24 GmbH
Overtech Corp. (OTCQB: OVET) Overtech Corp. (the "Company" or "Overtech") is pleased to provide an update regarding its acquisition of Beatmungspflege 24 GmbH (The "GmbH") announced on September 3, 2014.

Santhera to Present Results from Phase III Study with Catena®/ Raxone® in Duchenne Muscular Dystrophy at the International Congress of the World Muscle Society
Santhera Pharmaceuticals Holding AG /Santhera to Present Results from Phase III Study with Catena®/ Raxone® in Duchenne Muscular Dystrophy at the International Congress of the World Muscle Society . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Santhera Reports First Half 2014 Financial Results and Positive Developments in All Strategic Program
Santhera Pharmaceuticals Holding AG /Santhera Reports First Half 2014 Financial Results and Positive Developments in All Strategic Program . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Overtech to Purchase Leading German Intensive Care and Home Respiration Service Provider
Overtech Corp. (OTCQB: OVET) Overtech Corp. (the "Company" or "Overtech") announced today that it entered into a Share Purchase Agreement (the "Share Purchase Agreement") among Overtech, its wholly-owned subsidiary, Medicus Homecare Inc., Dr. Orhan Karahodza (the "Vendor"), Beatmungspflege 24 GmbH (the "GmbH") and Dr

Santhera Receives CHF 13.4 Million Through Sale of Treasury Shares
Santhera Pharmaceuticals Holding AG /Santhera Receives CHF 13.4 Million Through Sale of Treasury Shares . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Santhera Repositions Omigapil in Congenital Muscular Dystrophy and Initiates Clinical Development Program with Public-Private Partners
Santhera Pharmaceuticals Holding AG /Santhera Repositions Omigapil in Congenital Muscular Dystrophy and Initiates Clinical Development Program with Public-Private Partners . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

ValuationLAB issues research report on Santhera
Santhera Pharmaceuticals Holding AG /ValuationLAB issues research report on Santhera . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

European Medicines Agency Validates Santhera's Marketing Authorization Application for Raxone® in Leber's Hereditary Optic Neuropathy
Santhera Pharmaceuticals Holding AG /European Medicines Agency Validates Santhera's Marketing Authorization Application for Raxone® in Leber's Hereditary Optic Neuropathy . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Santhera Reports Positive Outcome for Catena®/Raxone® in Phase III DMD Trial Supported by Additional Respiratory Function Data
Santhera Pharmaceuticals Holding AG /Santhera Reports Positive Outcome for Catena®/Raxone® in Phase III DMD Trial Supported by Additional Respiratory Function Data . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Santhera's Shareholders Approve all Board Proposals at Annual Shareholders' Meeting
Santhera Pharmaceuticals Holding AG /Santhera's Shareholders Approve all Board Proposals at Annual Shareholders' Meeting . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

MYOS Corporation Reports 2014 First Quarter Results
MYOS Corporation (OTCBB: MYOS)

Santhera to Present at the Bio€quity 2014 Conference
Santhera Pharmaceuticals Holding AG /Santhera to Present at the Bio€quity 2014 Conference. Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Dr. George Kraft Named Recipient of the 4th Annual Kessler Foundation DeLisa Award
George H. Kraft, MD, MS, has been named the recipient of the 4th Annual Kessler Foundation's Joel A. DeLisa, MD Award for Excellence in Research and Education in the Field of Physical Medicine & Rehabilitation (PM&R), which includes a $50,000 unrestricted grant for his research activities. Dr. Kraft will be honored at Kessler Foundation's Board of Trustees dinner on May 8th.

Santhera's Phase III program with Catena®/Raxone® in Duchenne Muscular Dystrophy on track to deliver pivotal data early in 2Q 2014
Santhera Pharmaceuticals Holding AG /Santhera's Phase III program with Catena®/Raxone® in Duchenne Muscular Dystrophy on track to deliver pivotal data early in 2Q 2014 . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Santhera Secures Up to CHF 10 Million in Equity Financing From YA Global
Santhera Pharmaceuticals Holding AG /Santhera Secures Up to CHF 10 Million in Equity Financing From YA Global . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Jay Leno Grand Marshalls 30th Annual Charity Motorcycle Ride and Music Festival
GLENDALE, CA--(Marketwired - September 26, 2013) - Thousands are expected for the 30th anniversary Love Ride, led by Grand Marshall Jay Leno, with Jackson Browne, Jacksh*t, Chevy Metal, and The Forest Rangers with Katey Sagal on October 20, 2013

Santhera Closes License-Back Deal with Takeda For European Rights to Catena® in Duchenne Muscular Dystrophy
Santhera Pharmaceuticals Holding AG /Santhera Closes License-Back Deal with Takeda For European Rights to Catena® in Duchenne Muscular Dystrophy . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Non-Executive BoDs to Nominate Kees van der Graaf
Orascom Construction Inds, S.A.E. (LSE: ORSD)

Regen BioPharma Inc. Licenses Cancer Gene Silencing Technology From Benitec BioPharma
Bio-Matrix Scientific Group Inc. (OTCQB: BMSN) announced today that its wholly owned subsidiary, Regen BioPharma Inc. executed a license agreement with the clinical stage biotechnology company, Benitec Biopharma Ltd. (ASX: BLT) for the development of vaccines using Benitec's ddRNAi gene silencing technology.

Nicox First Half 2013 Financial Results and Business Update
Nicox S.A. (NYSE Euronext Paris: COX) today announced its financial results forthe six months ended June 30, 2013, and provided an update of itsactivities.

MK Battery Named Title Sponsor & Official Battery of the U.S. Power Soccer Assoc. and Team USA National Power Soccer Team
Mark Wels, President of MK Battery, and Ta'avasa Mamea, President of the United States Power Soccer Association (USPSA), jointly announced a multiyear agreement granting MK Battery the exclusive Title Sponsorship rights and Official Battery designation for all of the U.S

Nicox: first quarter 2013 financial results
Nicox S.A. (NYSE EuronextParis: COX) today reports financial results for thefirst three months of 2013 and provides an overview of its activities.

INSCOR, Inc. Appoints NBA Hall of Famer Dominique Wilkins to Board of Directors
INSCOR, Inc. (PINKSHEETS: IOGA) announces the addition of Dominique Wilkins to the Company's Board of Directors and appointment as Vice-Chairman. Wilkins' responsibilities will include acting as spokesman, promoting goodwill and developing INSCOR relations with professional athletes and sport associations

Santhera's Shareholders Support Business Continuation and Evaluation of Strategic Options
Santhera Pharmaceuticals Holding AG /Santhera's Shareholders Support Business Continuation and Evaluation of Strategic Options . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Pre-clinical results on naproxcinod in models of muscular dystrophy presented at MDA Scientific Conference
Nicox S.A. (EURONEXT PARIS: COX)today announced promising pre-clinicalresults on naproxcinod, a CINOD (Cyclooxygenase-Inhibiting NitricOxide-Donating) anti-inflammatory candidate, in models of musculardystrophies

Independent DSMB Recommends Continuation of Santhera's Phase III Trial of Catena® in Duchenne Muscular Dystrophy
Santhera Pharmaceuticals Holding AG /Independent DSMB Recommends Continuation of Santhera's Phase III Trial of Catena® in Duchenne Muscular Dystrophy . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Hope for 560 Million Patients Suffering From Rare Diseases
Due to the progress in genomics, we now know the cause of over 10,000 inherited diseases attributed to the malfunction of a single gene. The next step is to develop gene therapies

IAG's SoFit Continues Collaboration With Life Fitness and Augie's Quest, Displays at FIBO in Germany
InterAmerican Gaming Inc. ("IAG" or the "Company") (PINKSHEETS: IAGM) is pleased to announce the continued alliance with Life Fitness. The Company's operating subsidiary, SoFit Mobile Inc. ("SoFit") has developed a new social gaming platform for the health and fitness industry.

Thomson Reuters Corporation: Thomson Reuters Works with Children's Tumor Foundation to Advance Research Efforts
First-of-its-kind disease funding schemas provide a comprehensive view of neurofibromatosis research

AntriaBio Set for a Major Short Squeeze

Win a BMW 640i Convertible or a Share of $40,000 in Cash at Four Winds Casinos in April
The Pokagon Band of Potawatomi Indians' Four Winds® Casinos are pleased to announce that W Club members can win a BMW® 640i Convertible or a share of over $40,000 in cash at either Four Winds New Buffalo or Four Winds Hartford on Saturday, April 27. Hard Rock Cafe Four Winds will also host a St. Patrick's Day costume contest on Saturday, March 16

Dutch Bros. Coffee's Dutch Luv Day Brings In Over 200,000 Pounds of Food
This year, Dutch Bros. Coffee's Feb. 14 Dutch Luv Day tipped the scales with 205,322 pounds of food collected -- more than double last year's total -- for food banks across seven states.

Dutch Bros. Coffee Offers Valentine's Day Treat to Help Raise Food for Hungry Neighbors
Valentine's Day is Dutch Luv Day, when 195 Dutch Bros. Coffee locations in 94 cities will be offering drink specials in exchange for minimum canned food contributions to help their local food banks fight hunger.

PropThink: RPTP To Rise On Proven Strategy & Upcoming FDA Decision
By Ivan Deryugin

Sarepta Therapeutics to Present Company Overview at the 2013 31st Annual JP Morgan Healthcare Conference
Sarepta Therapeutics (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that it is scheduled to present at the 2013 31st Annual JP Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 9, 2013 at 4:30pm Pacific Time. Chris Garabedian, Sarepta's President and CEO, will be the presenter.

Sarepta Therapeutics Enters Into Clinical Trial Agreement With the National Institutes of Health for Further Development of Influenza Drug
Sarepta Therapeutics, Inc

Sarepta Therapeutics Announces a Continued Benefit on Walking Test Through 62 Weeks in Phase IIb Open-Label Extension Study of Eteplirsen in Duchenne Muscular Dystrophy
Sarepta Therapeutics (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced updated data from Study 202, its open-label, Phase IIb extension study of eteplirsen for the treatment of Duchenne muscular dystrophy (DMD)

Buck-4-Kids: Proceeds From 190 Dutch Bros. Coffee Locations to Benefit Youth Programs
On Friday, Dec. 7, all 190 Dutch Bros. Coffee locations in seven states will donate drink proceeds to youth programs selected by local owner-operators.

Sarepta Therapeutics to Present Company Overview at the Deutsche Bank 2012 dbAccess BioFEST Conference
Sarepta Therapeutics (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that it is scheduled to present at the Deutsche Bank 2012 dbAccess BioFEST Conference in Boston, MA on Tuesday, December 4, 2012 at 7:50 a.m. Eastern Time. Chris Garabedian, Sarepta's President and CEO, will be the presenter.

Sarepta Therapeutics Enters Into Collaboration for the Development of Additional Exon-Skipping Product for Duchenne Muscular Dystrophy
Sarepta Therapeutics (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today a collaboration for the development of an additional exon-skipping drug targeting exon 53, its fourth drug in development, in support of Sarepta's broad-based program for the treatment of Duchenne muscular dystrophy (DMD)

PropThink: Can Patients Scoop Clinical Trial Results?
By Jason Napodano, CFAIn the age of the Internet and social media portals such as Facebook and Twitter, investors are turning more and more to non-conventional sources of information to gain an advantage on investing in the stock market

Sarepta Therapeutics Names Sandy Mahatme Senior Vice President, Chief Financial Officer and Ty Howton Senior Vice President, General Counsel
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced the appointment of Sandesh "Sandy" Mahatme, senior vice president, chief financial officer, and David Tyronne "Ty" Howton, senior vice president, general counsel, effective today.

Sarepta Therapeutics Announces Third Quarter 2012 Financial Results and Recent Corporate Developments
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today reported financial results for the three and nine months ended September 30, 2012, and provided an update of recent corporate developments.

Sarepta Therapeutics to Present Additional 48-Week Data From the Phase IIb Study of Eteplirsen for the Treatment of Duchenne Muscular Dystrophy at the 17th Annual International World Muscle Society
Sarepta Therapeutics (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that data from a Phase IIb study evaluating eteplirsen, an investigational treatment for boys with Duchenne muscular dystrophy (DMD), will be presented Saturday, October 13th at the World Muscle Society in Perth, Australia. Principal investigator, Jerry R. Mendell, M.D

Benitec Announces Acquisition of Tacere Therapeutics and Phase I/II Ready Hepatitis C (HCV) Program
Benitec Biopharma (ASX: BLT)

Sarepta Therapeutics Receives Notice From Department of Defense for Termination of Ebola Therapeutic Program
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, received notice from the U.S. Department of Defense (DoD) that the Ebola portion of the Company's contract for the advanced development of hemorrhagic fever virus therapeutics was terminated for the convenience of the government due to funding constraints

Sarepta Therapeutics Announces Eteplirsen Meets Primary Endpoint of Increased Novel Dystrophin and Achieves Significant Clinical Benefit on 6-Minute Walk Test After 48 Weeks of Treatment in Phase IIb Study in Duchenne Muscular Dystrophy

Sarepta Therapeutics Announces Conference Call and Webcast on Wednesday, October 3, 2012, to Discuss 48-Week Results From the Phase IIb DMD Study
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today it will hold a conference call at 8:00 a.m. EDT (5:00 a.m. PDT) on Wednesday, October 3, 2012 to discuss 48-week results from its Phase IIb study evaluating eteplirsen for the treatment of Duchenne muscular dystrophy (DMD).

Sarepta Therapeutics' Lead Therapeutic Drugs for Ebola and Marburg Viruses Receive FDA Fast Track Designation
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track status for the development of its lead infectious disease drug candidates, AVI-7288 and AVI-7537, for the treatment of Marburg virus and Ebola virus, respectively

Phrixus Pharmaceuticals, Inc. Receives Notice of Allowance for Additional U.S. Patent on Carmeseal(TM) (Poloxamer-188)
Phrixus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on innovative therapies for Duchenne muscular dystrophy (DMD) and heart failure, announced today that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application Serial Number 12/593,798, titled "Compositions and methods for the treatment of heart failure

Dutch Bros. Donating Proceeds From "Be Aware" Mugs to Breast Cancer Screenings
The entire month of October, National Breast Cancer Awareness month, Dutch Bros. Coffee will be selling pink "Be Aware" travel mugs and donating proceeds to breast cancer screenings for women who are uninsured or underinsured.

Sarepta Therapeutics Announces Presentation at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting
Sarepta Therapeutics (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that the Company's therapeutic candidate AVI-7288 for the treatment of Marburg virus will be featured in a presentation at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting taking place September 9-12, 2012 in San Francisco, CA.

Sarepta Therapeutics Announces At-the-Market Equity Offering
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, entered into an At-the-Market (ATM) equity offering sales agreement with Citadel Securities LLC on September 4, 2012, under which Sarepta may, from time to time, offer and sell shares of its common stock having an aggregate value of up to $40 million through Citadel

Dutch Bros. Coffee Raises $93,000 on Annual Buck For Kids Day
This month, in support of Dutch Bros.' mantra "make a difference one cup at a time," the company's customers helped raise $93,000 to benefit regional nonprofits. The donation is the result of Dutch Bros.' annual Buck For Kids Day, an event during which all 173 locations give a portion of their proceeds to the community.

USDA Issues Notice of Withdrawal Against Wildlife WayStation Supporter
The RHL Group, Inc. (www.rhlgroup.com) today announced that the United States Department of Agriculture (USDA) has issued a withdrawal of a complaint against its Chairman and CEO, Robert H. Lorsch, in connection with his philanthropic contributions to the Wildlife WayStation as its Best Friend, Financial Supporter and Director

Wildlife WayStation Supporter Files Claim Against the U.S. Department of Agriculture Arising From Efforts to Help Animals
The RHL Group, Inc. (www.rhlgroup.com) today announced that Bob Lorsch, the company's chairman, has filed a four million dollar Federal Tort Claim against the United States Department of Agriculture (USDA) following procedures required before filing a lawsuit for Malicious Prosecution and other possible claims

AVI BioPharma Receives NASDAQ Notice of Minimum Bid Price Non-Compliance
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, announced today that it received a letter from the listing qualifications department staff of The NASDAQ Stock Market LLC, notifying AVI that for the last 30 consecutive business days the bid price of its common stock had closed below $1

Children's Music Fund Bringing Holiday Cheer to Children at White Memorial Medical Center
On December 12, 2011, Children's Music Fund (CMF) will help bring some much-needed magic to the children in White Memorial Medical Center's Cleft Palate program. CMF, in partnership with CoachArt, is sponsoring interactive children's activities and entertainment at the medical center's annual Christmas party

AVI BioPharma Names Jayant Aphale, Ph.D., Senior Vice President of Technical Operations
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, today announced the appointment of Jayant Aphale, Ph.D., as Senior Vice President of Technical Operations effective December 12, 2011. Dr

AVI BioPharma to Present Company Overview at the Piper Jaffray Health Care Conference
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, announced today that the Company is scheduled to present at the Piper Jaffray Health Care Conference in New York, NY, on Tuesday, November 29, at 8:30 a.m. Eastern Time. Chris Garabedian, AVI's President and CEO, will provide a company overview.

First Dutch Bros. Coffee "Rock Star" Location Opens Today
Dutch Bros. Coffee has opened its first "Employee Rock Star" location today, Tuesday, Nov. 22, in Moses Lake, Wash. In May, Dutch Bros. announced Kristen Ennis Nelson, 26, the winner of the inaugural contest in which Dutch Bros. bestows an outstanding employee with their own store.

AVI Enters Into Collaborations for the Development of Two Additional Exon-Skipping Products for Duchenne Muscular Dystrophy (DMD)
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, today announced collaborations for the development of two additional exon-skipping drugs, one for exon 45 and one for exon 50, to support AVI's broad-based development program for the treatment of DMD. AVI's collaboration with Children's National Medical Center in Washington, D.C

Gene tweaked 'marathon mice' may pave way for human musclemen
Treatments that can increase muscle strength of humans may soon be within reach, a new study has suggested.

Comment on this story

Share